GNRH1 and osteoporosis: Long-term GnRH agonist use can cause hypoestrogenic symptoms, such as vasomotor symptoms and osteoporosis; thus, requiring follow-up on patient tolerance, serum estrogen status, and bone mineral density, especially in premenopausal women.